Search alternatives:
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 de » 2 d (Expand Search), _ de (Expand Search), i de (Expand Search)
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 de » 2 d (Expand Search), _ de (Expand Search), i de (Expand Search)
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
PPM1A facilitates both nuclear distribution and transcription potency of YAP/TAZ.
Published 2021“…<b>(B–D)</b> Transcription potency of YAP (5 ng), which was suppressed by coexpression of MST1 (50 ng) (B), LATS1 (500 ng) (C), or MAP4K1 (50 ng) (D), was markedly recovered by cotransfection of wild-type PPM1A but not the enzyme-dead PPM1A (D239N). …”
-
95
Aquaporin 2 Mutations in <i>Trypanosoma brucei gambiense</i> Field Isolates Correlate with Decreased Susceptibility to Pentamidine and Melarsoprol
Published 2013“…Here we describe two different kinds of <i>TbAQP2</i> mutations found in <i>T. b. gambiense</i> field isolates: simple loss of <i>TbAQP2</i>, or loss of wild-type <i>TbAQP2</i> allele combined with the formation of a novel type of <i>TbAQP2/3</i> chimera. The identified mutant <i>T. b. gambiense</i> are 40- to 50-fold less sensitive to pentamidine and 3- to 5-times less sensitive to melarsoprol than the reference isolates. …”
-
96
-
97
-
98
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
99
-
100